Featured Presentations Corporate Presentation Data Publications REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB REGENXBIO Rare Disease Program Update Presentation 704.9 KB REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB Upcoming Events More events are coming soon. Past Events More events are coming soon. Pagination First page « Previous page ‹ Page 1 Current page 2
REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB
REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB
REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB
REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB
REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB
REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB
